Literature DB >> 21191066

A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells.

Tim D Holmes1, Yasser M El-Sherbiny, Adam Davison, Sally L Clough, G Eric Blair, Graham P Cook.   

Abstract

NK cell activation is negatively regulated by the expression of target cell MHC class I molecules. We show that this relationship is nonlinear due to an NK cell activation/inhibition threshold. Ewing's sarcoma family tumor cell monolayers, which were highly susceptible to NK cells in vitro, developed a highly resistant phenotype when cultured as three-dimensional multicellular tumor spheroid structures. This suggested that tumor architecture is likely to influence the susceptibility to NK cells in vivo. Resistance of the multicellular tumor spheroid was associated with the increased expression of MHC class I molecules and greatly reduced NK cell activation, implying that a threshold of NK cell activation/inhibition had been crossed. Reducing MHC class I expression on Ewing's sarcoma family tumor monolayers did not alter their susceptibility to NK cells, whereas increased expression of MHC class I rendered them resistant and allowed the threshold point to be identified. This threshold, as defined by MHC class I expression, was predictive of the number of NK-resistant target cells within a population. A threshold permits modest changes in the target cell surface phenotype to profoundly alter the susceptibility to NK cells. Whereas this allows for the efficient detection of target cells, it also provides a route for pathogens and tumors to evade NK cell attack.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21191066     DOI: 10.4049/jimmunol.1000951

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Authors:  Sareetha Kailayangiri; Bianca Altvater; Christian Spurny; Silke Jamitzky; Sonja Schelhaas; Andreas H Jacobs; Constanze Wiek; Katharina Roellecke; Helmut Hanenberg; Wolfgang Hartmann; Heinz Wiendl; Susann Pankratz; Jutta Meltzer; Nicole Farwick; Lea Greune; Maike Fluegge; Claudia Rossig
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

2.  Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT.

Authors:  Tim D Holmes; Erica B Wilson; Emma V I Black; Andrew V Benest; Candida Vaz; Betty Tan; Vivek M Tanavde; Graham P Cook
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

3.  MicroRNA-deficient NK cells exhibit decreased survival but enhanced function.

Authors:  Ryan P Sullivan; Jeffrey W Leong; Stephanie E Schneider; Catherine R Keppel; Elizabeth Germino; Anthony R French; Todd A Fehniger
Journal:  J Immunol       Date:  2012-02-29       Impact factor: 5.422

Review 4.  Adoptive cell therapy for sarcoma.

Authors:  Melinda Mata; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 5.  Tissue engineered models of healthy and malignant human bone marrow.

Authors:  Alan Chramiec; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2019-04-17       Impact factor: 15.470

6.  Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.

Authors:  Conor J Kearney; Kelly M Ramsbottom; Ilia Voskoboinik; Phillip K Darcy; Jane Oliaro
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

Review 7.  3D tissue-engineered model of Ewing's sarcoma.

Authors:  Salah-Eddine Lamhamedi-Cherradi; Marco Santoro; Vandhana Ramammoorthy; Brian A Menegaz; Geoffrey Bartholomeusz; Lakesla R Iles; Hesham M Amin; J Andrew Livingston; Antonios G Mikos; Joseph A Ludwig
Journal:  Adv Drug Deliv Rev       Date:  2014-08-07       Impact factor: 15.470

8.  Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression.

Authors:  Pilar M Lanuza; Alan Vigueras; Sara Olivan; Anne C Prats; Santiago Costas; Guillermo Llamazares; Diego Sanchez-Martinez; José María Ayuso; Luis Fernandez; Ignacio Ochoa; Julián Pardo
Journal:  Oncoimmunology       Date:  2018-02-12       Impact factor: 8.110

9.  Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.

Authors:  Henry Ogbomo; Franz J Zemp; Xueqing Lun; Jiqing Zhang; Danuta Stack; Masmudur M Rahman; Grant McFadden; Christopher H Mody; Peter A Forsyth
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

10.  The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation.

Authors:  Florencia Cano; Helen Bye; Lidia M Duncan; Karine Buchet-Poyau; Marc Billaud; Mark R Wills; Paul J Lehner
Journal:  EMBO J       Date:  2012-08-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.